Uniqure NV (NASDAQ:QURE) Director Philip Astley-Sparke sold 6,460 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $60.12, for a total transaction of $388,375.20. Following the completion of the sale, the director now owns 12,406 shares of the company’s stock, valued at $745,848.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Philip Astley-Sparke also recently made the following trade(s):
- On Monday, June 3rd, Philip Astley-Sparke sold 6,000 shares of Uniqure stock. The stock was sold at an average price of $63.63, for a total transaction of $381,780.00.
Uniqure stock opened at $56.61 on Thursday. Uniqure NV has a 1-year low of $21.98 and a 1-year high of $82.49. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -24.19 and a beta of 0.94. The firm has a fifty day simple moving average of $70.48. The company has a debt-to-equity ratio of 0.51, a current ratio of 8.07 and a quick ratio of 8.07.
Institutional investors have recently added to or reduced their stakes in the business. Harvest Group Wealth Management LLC bought a new position in shares of Uniqure in the first quarter valued at $26,000. Pearl River Capital LLC bought a new position in shares of Uniqure in the first quarter valued at $32,000. Legal & General Group Plc lifted its stake in shares of Uniqure by 264.2% in the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 700 shares in the last quarter. Botty Investors LLC bought a new position in shares of Uniqure in the second quarter valued at $78,000. Finally, Aperio Group LLC bought a new position in shares of Uniqure in the second quarter valued at $83,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.
QURE has been the subject of a number of research reports. Janney Montgomery Scott restated a “buy” rating on shares of Uniqure in a report on Tuesday, June 11th. BidaskClub cut shares of Uniqure from a “sell” rating to a “strong sell” rating in a report on Thursday. HC Wainwright set a $73.00 price target on shares of Uniqure and gave the stock a “buy” rating in a report on Monday, July 8th. Zacks Investment Research cut shares of Uniqure from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. Finally, Guggenheim cut shares of Uniqure from a “buy” rating to a “neutral” rating in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. Uniqure presently has an average rating of “Buy” and an average price target of $78.18.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.